Your browser is no longer supported. Please, upgrade your browser.
Alpine Immune Sciences, Inc.
Index- P/E- EPS (ttm)-1.49 Insider Own1.60% Shs Outstand23.91M Perf Week10.74%
Market Cap238.00M Forward P/E- EPS next Y-1.40 Insider Trans-22.94% Shs Float17.25M Perf Month15.21%
Income-34.20M PEG- EPS next Q-0.02 Inst Own55.20% Short Float4.45% Perf Quarter8.70%
Sales18.00M P/S13.22 EPS this Y41.20% Inst Trans-4.27% Short Ratio7.67 Perf Half Y-21.57%
Book/sh1.83 P/B5.46 EPS next Y-6.90% ROA-23.20% Target Price- Perf Year20.05%
Cash/sh3.82 P/C2.62 EPS next 5Y- ROE-60.20% 52W Range7.21 - 16.37 Perf YTD-20.63%
Dividend- P/FCF- EPS past 5Y-12.60% ROI-39.80% 52W High-38.91% Beta1.68
Dividend %- Quick Ratio2.30 Sales past 5Y80.10% Gross Margin- 52W Low38.70% ATR0.46
Employees57 Current Ratio2.30 Sales Q/Q928.60% Oper. Margin- RSI (14)60.73 Volatility5.44% 4.56%
OptionableYes Debt/Eq0.24 EPS Q/Q13.60% Profit Margin- Rel Volume1.46 Prev Close9.95
ShortableYes LT Debt/Eq0.13 EarningsAug 10 AMC Payout- Avg Volume100.01K Price10.00
Recom1.60 SMA206.89% SMA5011.16% SMA200-9.52% Volume145,754 Change0.50%
Dec-21-20Initiated H.C. Wainwright Buy $21
Aug-26-20Initiated Cowen Outperform
Sep-15-21 08:05AM  
Sep-07-21 04:05PM  
Aug-18-21 06:04AM  
Aug-10-21 05:45PM  
Aug-04-21 08:00AM  
Aug-03-21 03:00PM  
Jul-30-21 09:55AM  
Jul-24-21 03:25AM  
Jul-01-21 10:51AM  
Jun-30-21 08:00AM  
Jun-24-21 08:00AM  
Jun-13-21 05:28AM  
Jun-08-21 08:00AM  
Jun-04-21 04:05PM  
Jun-03-21 08:14AM  
Jun-02-21 04:05PM  
May-23-21 06:43AM  
May-20-21 04:47AM  
May-19-21 05:10PM  
May-18-21 04:05PM  
May-13-21 06:45PM  
May-06-21 03:00PM  
May-05-21 01:41AM  
Apr-28-21 04:05PM  
Apr-16-21 08:28AM  
Apr-12-21 08:00AM  
Mar-21-21 03:30AM  
Mar-19-21 12:00AM  
Mar-18-21 05:35PM  
Mar-11-21 04:05PM  
Mar-10-21 04:30PM  
Feb-22-21 04:05PM  
Feb-03-21 11:36PM  
Jan-06-21 08:00AM  
Jan-01-21 07:04AM  
Dec-21-20 10:07AM  
Dec-20-20 11:29PM  
Dec-17-20 08:00AM  
Dec-11-20 10:23PM  
Dec-08-20 08:35AM  
Nov-24-20 04:05PM  
Nov-16-20 04:05PM  
Nov-15-20 07:03AM  
Nov-12-20 04:05PM  
Nov-05-20 04:05PM  
Oct-28-20 06:32AM  
Sep-15-20 04:05PM  
Sep-08-20 04:05PM  
Aug-26-20 09:42AM  
Aug-11-20 04:05PM  
Aug-05-20 04:05PM  
Aug-04-20 04:05PM  
Jul-24-20 09:15AM  
Jul-22-20 06:45AM  
Jul-08-20 09:05AM  
Jun-25-20 12:09PM  
Jun-24-20 08:00AM  
Jun-19-20 11:27AM  
Jun-18-20 10:22AM  
Jun-15-20 08:00AM  
Jun-11-20 06:57AM  
Jun-10-20 03:44PM  
Jun-08-20 08:00AM  
Jun-04-20 08:00AM  
May-29-20 08:00AM  
May-26-20 04:05PM  
May-16-20 08:11AM  
May-14-20 04:01PM  
Apr-27-20 09:00AM  
Apr-20-20 04:05PM  
Apr-13-20 06:15AM  
Apr-07-20 07:06AM  
Mar-30-20 04:01PM  
Mar-18-20 07:15AM  
Mar-02-20 04:05PM  
Feb-25-20 04:02PM  
Jan-24-20 07:30AM  
Jan-14-20 06:17AM  
Jan-06-20 07:30AM  
Dec-22-19 01:52PM  
Dec-09-19 07:30AM  
Nov-26-19 07:30AM  
Nov-13-19 04:05PM  
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated autoimmune/inflammatory diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the research, development, and commercialization of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GOLD MITCHELLExecutive Chairman and CEOSep 16Sale10.006,76867,696154,649Sep 17 06:06 PM
GOLD MITCHELLExecutive Chairman and CEOSep 15Sale10.003,48434,840161,417Sep 17 06:06 PM
GOLD MITCHELLExecutive Chairman and CEOJun 28Sale10.003,47934,792164,901Jun 29 05:13 PM
GOLD MITCHELLExecutive Chairman and CEOJun 25Sale10.019,47394,865168,380Jun 29 05:13 PM
GOLD MITCHELLExecutive Chairman and CEOMay 20Sale15.001,22118,316177,853May 21 05:16 PM
GOLD MITCHELLExecutive Chairman and CEOMay 19Sale15.0350,965765,917179,074May 21 05:16 PM
GOLD MITCHELLExecutive Chairman and CEOMay 13Sale11.5210,000115,169230,039May 14 05:17 PM
GOLD MITCHELLExecutive Chairman and CEOMay 12Sale11.6810,000116,842240,039May 14 05:17 PM
GOLD MITCHELLExecutive Chairman and CEOApr 14Sale10.5210,000105,200250,039Apr 15 06:09 PM
GOLD MITCHELLExecutive Chairman and CEOApr 13Sale10.0710,000100,714260,039Apr 15 06:09 PM
Venkatesan JayDirectorMar 31Option Exercise3.627,65027,718218,063Apr 23 06:14 PM
Venkatesan JayDirectorMar 30Option Exercise4.097,65031,288210,413Apr 23 06:14 PM
GOLD MITCHELLExecutive Chairman and CEOMar 05Sale12.9910,000129,875270,039Mar 08 05:01 PM
GOLD MITCHELLExecutive Chairman and CEOMar 04Sale13.0110,000130,108280,039Mar 08 05:01 PM
GOLD MITCHELLExecutive Chairman and CEOFeb 02Sale11.7410,000117,381290,039Feb 03 05:01 PM
GOLD MITCHELLExecutive Chairman and CEOFeb 01Sale12.8710,000128,665300,039Feb 03 05:01 PM
ORBIMED ADVISORS LLCDirectorDec 28Sale14.25600,0008,550,0003,070,955Dec 30 04:44 PM
Thompson Peter A.DirectorDec 28Sale14.25600,0008,550,0003,070,955Dec 30 04:38 PM
CONWAY ROBERT EDirectorNov 19Buy8.0310,00080,30025,000Nov 23 05:00 PM